Educational reference only. Not medical advice. Consult a healthcare provider before starting any protocol.
Oxytocin
Oxytocin (Pitocin)
What it is
A cyclic nonapeptide neurohormone produced in the hypothalamus and released by the posterior pituitary. Oxytocin is FDA-approved as Pitocin for labor induction, labor augmentation, and management of postpartum hemorrhage. It is one of the most extensively studied peptide hormones in existence and was the first to be sequenced and synthesized (Vincent du Vigneaud, 1953 Nobel Prize). Beyond its established obstetric indications, intranasal oxytocin has been investigated in over 1,500 clinical trial participants for social cognition, anxiety, autism spectrum disorder, and PTSD, though results have been inconsistent and methodologically debated. In biohacking and integrative medicine communities, compounded intranasal oxytocin is discussed in the context of social bonding, stress reduction, and mood support.
Community-reported ranges
Obstetric dosing from FDA Pitocin label. Intranasal ranges converted from IU to mcg (1 IU ≈ 1.68 mcg): typically 24 IU (~40 mcg) single dose, compounding pharmacy protocols 10-20 IU (~17-34 mcg). Not dosing guidance.
Reported dose range
17–40 mcg
Estimated half-life
~3 min (IV); ~30 min apparent (intranasal plasma)
Source: FDA label (IV); clinical pharmacokinetic studies (intranasal)
Reported cycle length
4–12 weeks on
Not well established for intranasal use weeks off
Route
intravenous, intramuscular, intranasal
Common vial sizes
10 IU/mL ampule, 50 IU/mL nasal spray, 100 IU/mL nasal spray
Reported timing
As needed (obstetric); AM or before social situations (off-label intranasal)
Reported frequency
1-2x daily (intranasal, off-label); continuous IV infusion (obstetric, FDA-approved)
Frequently discussed alongside
Based on community forum discussions. Not a recommendation to combine compounds.
Published research
Oxytocin is a well-characterized, FDA-approved nonapeptide with decades of obstetric use. Off-label intranasal application for psychiatric and social-cognitive conditions (autism, social anxiety, PTSD, depression) is an active but methodologically contested research area. A 2020 systematic review flagged low statistical power and limited replication across intranasal studies. The peptide's extremely short IV half-life limits systemic applications, but nose-to-brain transport provides a practical non-invasive delivery pathway with a favorable short-term safety profile. Community use of compounded intranasal sprays for mood and bonding support is widespread but not supported by robust chronic-use safety data.
Reported side effects
From community self-reports. Not from controlled studies.
IV/IM (FDA label): water intoxication and hyponatremia with prolonged infusion, uterine hyperstimulation, uterine rupture (rare), cardiac arrhythmias, nausea, and vomiting. Intranasal (clinical trials): a systematic review of 38 RCTs (N=1,529) found side effects were not statistically different from placebo. Mild reported effects include nasal discomfort, tiredness, and irritability. Long-term intranasal safety data remains limited.
Regulatory status
FDA (United States)
FDA-approved as Pitocin (NDA 018261) for labor induction, labor augmentation, incomplete/inevitable abortion management, and postpartum hemorrhage. Intranasal formulation is not separately FDA-approved but is available through 503A/503B compounding pharmacies. On the WHO Essential Medicines List.
Health Canada
Approved. Oxytocin Injection USP holds multiple DINs in the Health Canada Drug Product Database for obstetric indications.
WADA (Competitive Athletes)
Not prohibited. Oxytocin is not listed under S2 (Peptide Hormones) or any other category on the WADA Prohibited List.
Requires free account · 7-day trial included